TIME Magazine Names Xenco Medical One of the 100 Most Influential Companies in the World and the Winner of the 2026 TIME100 Impact Award in Health

In a year marked by accelerating transformation across healthcare, few recognitions carry the weight, or signal the trajectory, of inclusion on the TIME100 Most Influential Companies list. In 2026, San Diego–headquartered Xenco Medical not only earned a place among this elite cohort but also distinguished itself as the sole recipient of the TIME100 Impact Award in Health, an honor reserved for organizations delivering measurable, global change.

For spine and orthopedic leaders, the recognition underscores a broader shift: innovation is no longer defined by devices alone, but by integrated ecosystems that reshape how care is delivered, monitored, and valued.

A Rare Distinction in Global Healthcare Innovation

The TIME100 Impact Awards are notably selective, with just five companies worldwide recognized annually across all industries. Xenco Medical's selection as the only honoree in healthcare places it in a category of its own, signaling influence that extends well beyond product development into systemic transformation.

According to TIME, the list highlights organizations "making an extraordinary impact around the world." For Xenco, that impact is rooted in a convergence of biologics, digital health, and surgical efficiency, an increasingly critical triad in spine care.

This latest recognition builds on a momentum of accolades. In 2025 alone, the company was named Medical Device/Diagnostics Company of the Year at the Trailblazer Awards, recognized by Fast Company as one of the World's Most Innovative Companies for the second time, and honored by the World Economic Forum for excellence in governance and leadership addressing global challenges.

"We are immensely honored and profoundly humbled to be named the 2026 Winner of the TIME100 Impact in Health Award and a TIME100 Most Influential Company in the World. As a mission-driven company animated by the relentless pursuit of delivering the greatest outcomes to the greatest number of patients, this recognition by TIME has only deepened our commitment to translate the promise of science into a transformative impact on the lives of our patients and their families," said Xenco Medical Founder and CEO Jason Haider.

Redefining the Spine Care Continuum

At the center of Xenco Medical's rise is its ability to unify traditionally fragmented elements of care. Its portfolio spans biomimetic implants, regenerative biomaterials, and composite polymer-based surgical systems, paired with a growing suite of digital platforms that extend care far beyond the operating room.

The company's TrabeculeX Continuum platform illustrates this shift toward connected care. By combining osteogenic biomaterials with AI-driven postoperative monitoring, the platform enables surgeons to track patient recovery in real time, capturing metrics such as pain levels, rehabilitation adherence, and functional mobility through remote, AI-based motion analysis.

For spine surgeons, this represents a meaningful evolution. Postoperative recovery, long considered difficult to quantify outside clinical visits, is now becoming measurable, continuous, and actionable.

Operational Efficiency Meets Value-Based Care

Beyond clinical innovation, Xenco Medical is also addressing one of healthcare's most pressing challenges: efficiency. Its single-use, logistics-driven surgical systems eliminate the need for sterilization and reprocessing, reducing turnover times and streamlining workflows in high-volume surgical environments.

This operational model aligns directly with the ongoing transition toward value-based care. By reducing procedural friction while enhancing patient outcomes, the company is positioning itself at the intersection of cost containment and quality improvement, a balance increasingly demanded by health systems and payors alike.

A Blueprint for the Future of Spine Innovation

Xenco Medical's recognition by TIME reflects more than a single company's success; it signals a broader recalibration of what defines leadership in healthcare innovation.

For spine and orthopedic stakeholders, the implications are clear: integration is overtaking specialization, data-driven recovery is becoming standard, efficiency is no longer optional, it's strategic.

As the industry continues to evolve, companies that bridge biologics, digital health, and surgical delivery systems will likely shape the next decade of care. Xenco Medical's ascent to the heights of global business suggests that the future of medical innovation won't be built in silos, but in connected, intelligent ecosystems designed to improve outcomes at every stage of the patient journey.